NASDAQ$OBIO
Orchestra Biomed Holdings In · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Orchestra BioMed reported Q1 2026 with $110K revenue, net loss of $20.7M.
For the period ended 2026-03-31, Orchestra BioMed reported $110K revenue. Revenue $0.1M; partnership with Medtronic. Net loss attributable to common $20.7M. Cardiovascular device platform; revenue tied to partnership milestones.
- Revenue $0.1M; partnership with Medtronic.
- Net loss attributable to common $20.7M.
- Minimal revenue.
Headline financials
Revenue & EPS history
Orchestra Biomed · Revenue · Quarterly
$110K
Revenue by segment
Orchestra Biomed · $2.64M total across 2 segments · Q4 2024
- Partnership revenue$2.01M-4.8%76.0%
- Product revenue$633K-3.2%24.0%
Forward guidance
Cardiovascular device platform; revenue tied to partnership milestones.
Tailwinds
- Medtronic partnership.
- Product revenue beginning.
Headwinds
- Minimal revenue.
- Clinical and regulatory milestones ahead.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2026
+4.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+5.7%
Avg return
30 days after
63%
12 / 19 earnings
Positive
+30.5%
Q4 2022
Best reaction
-6.0%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -4.9% | +4.1% | |
| Q4 2025 | +4.7% | +4.9% | -2.0% | |
| Q3 2025 | +4.6% | +12.4% | +9.1% | |
| Q2 2025 | -2.6% | +1.8% | +4.0% | |
| Q1 2025 | +0.3% | -5.9% | +16.6% | |
| Q4 2024 | -6.0% | -4.4% | -11.1% | |
| Q3 2024 | -1.0% | -4.7% | -12.9% | |
| Q2 2024 | -3.7% | +3.7% | -8.1% | |
| Q1 2024 | +10.4% | +10.6% | +68.6% | |
| Q4 2023 | +0.2% | -5.9% | -16.5% | |
| Q3 2023 | +29.6% | +28.8% | +58.3% | |
| Q2 2023 | +5.3% | -0.5% | +9.2% | |
| Q1 2023 | +2.5% | +15.3% | -16.8% | |
| Q4 2022 | +30.5% | -12.1% | -1.6% | |
| Q3 2022 | +0.3% | -0.4% | +0.1% | |
| Q2 2022 | +0.0% | +0.1% | +0.2% | |
| Q4 2021 | +0.0% | +0.2% | +0.4% | |
| Q1 2022 | +0.0% | +0.2% | +0.4% | |
| Q1 2021 | +3.7% | +1.8% | +6.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro